Sera Prognostics Q2 Earnings Call Highlights
MarketBeat
Sera Prognostics (NASDAQ:SERA) reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform.
Revenue for the quarter ended June 30 was $30,000, compared
NASDAQ:SERA